# Primary Hyperparathyroidism

Confirm PTH-dependent hypercalcemia biochemically, exclude familial hypocalciuric hypercalcemia before an operation, assess skeletal and renal involvement, and offer parathyroidectomy as definitive treatment. Use localization imaging for operative planning rather than diagnosis, with medical therapy or surveillance reserved for selected patients.

**Clinical question:** How should physicians confirm primary hyperparathyroidism, select patients for parathyroidectomy, and manage those not undergoing surgery?

Updated: 2026-09-16T00:36:47.664879+00:00

## What matters in practice
- Diagnose PHPT from hypercalcemia with an increased or inappropriately normal PTH; a PTH within the laboratory reference interval is not physiologically appropriate in hypercalcemia. [16][21]
- Before parathyroidectomy, distinguish PHPT from FHH with 24-hour urine calcium and calcium-creatinine clearance ratio; hypocalciuria below 100 mg/24 hours and a ratio below 0.02 favor FHH. [9][21]
- Refer all symptomatic patients for parathyroidectomy; it is the only definitive therapy and should also be considered in most asymptomatic patients. [4][6][24]
- Use imaging after biochemical diagnosis to localize operative targets, not to establish PHPT; negative or discordant localization does not preclude parathyroidectomy. [2][23]
- For patients declining or unable to undergo surgery, do not restrict dietary calcium; replete low 25-hydroxyvitamin D to at least 20 ng/mL, with 30 ng/mL a reasonable goal, and consider cinacalcet when calcium reduction is the therapeutic objective. [13][24]

## Confirm PHPT before ordering localization imaging

The diagnostic pivot is the calcium-PTH relationship, not an isolated PTH result.

Establish PHPT biochemically when serum calcium is elevated and PTH is increased or nonsuppressed. In a hypercalcemic patient, a PTH that falls within the assay reference interval remains inappropriately high and supports PTH-dependent hypercalcemia. This relationship is more useful than requiring both calcium and PTH to be above their reference ranges. [16][21]

Measure serum phosphate as a severity adjunct, not as a stand-alone diagnostic test. In a cohort of 472 patients with PHPT, phosphate below 2.5 mg/dL occurred in 41.9%; moderate hypophosphatemia of 1 to 1.9 mg/dL identified patients who were all symptomatic or met operative criteria. Lower phosphate was associated with higher calcium and PTH concentrations and more renal stones. [19]

Do not use sestamibi, ultrasonography, or other localization studies to decide whether PHPT is present. Obtain imaging only after biochemical confirmation and a decision to pursue surgery, because its role is localization of operative targets. Imaging is important for adenoma localization, but patients with negative or discordant studies may still undergo unilateral parathyroidectomy in selected settings. [2][23]
- A normal-range PTH does not exclude PHPT when calcium is high; interpret it as nonsuppressed rather than normal. [21]
- Hypophosphatemia below 2.5 mg/dL supports greater biochemical disease burden but does not replace calcium-PTH confirmation. [19]
- Order localization imaging for the surgeon's operative plan, not for diagnostic confirmation. [23]

*Biochemical findings that change the next diagnostic step. [9][16][19][21]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Elevated calcium with increased or nonsuppressed PTH | PTH-dependent hypercalcemia consistent with PHPT after competing causes are assessed. [16][21] | Evaluate urinary calcium to distinguish FHH, then assess operative candidacy. [9][21] |
| 24-hour urine calcium <100 mg/24 hours | Hypocalciuria favors FHH over PHPT. [21] | Calculate calcium-creatinine clearance ratio and reassess the appropriateness of parathyroidectomy. [9][21] |
| Calcium-creatinine clearance ratio <0.02 | A cost-effective discriminator favoring FHH; values <0.01 were documented in an FHH case. [9] | Avoid assuming a curative operation; consider heritable calcium-sensing receptor disease in the clinical context. [9] |
| Serum phosphate 1-1.9 mg/dL | Moderate hypophosphatemia correlated with symptomatic disease or established surgical indications in one PHPT cohort. [19] | Expedite assessment for renal and skeletal operative indications. [19] |

## Exclude FHH and identify patients needing germline evaluation

The key preoperative error is operating on inherited hypocalciuric hypercalcemia as though it were sporadic PHPT.

In a patient with hypercalcemia and nonsuppressed PTH, obtain a 24-hour urine calcium and calculate the calcium-creatinine clearance ratio before committing to parathyroidectomy. FHH can resemble PHPT biochemically but is characterized by hypocalciuria, commonly below 100 mg/24 hours; a clearance ratio below 0.02 is a practical discriminator favoring FHH. Persistent hypercalcemia after parathyroid surgery has been reported when FHH coexists with or is mistaken for PHPT. [9][21]

Offer genetic testing for heritable PHPT to patients with onset at age 40 years or younger, multiglandular disease, recurrent PHPT, or a family history of PHPT. Approximately 15% of PHPT has an underlying heritable form; recognizing this changes surveillance because MEN1 and MEN2A may carry extraparathyroid neoplasia risks. [20]

For a high-risk familial phenotype, testing panels commonly include MEN1, RET, CDKN1B, and CDC73. Features increasing suspicion include young onset, a family history, multiglandular disease, hyperparathyroidism-jaw tumor phenotype, cystic parathyroid adenoma, and parathyroid carcinoma. [14]
- Do not infer FHH solely from a low urine calcium result; use the calcium-creatinine clearance ratio and the clinical context. [9][21]
- A biochemical profile compatible with FHH should pause a planned operation because FHH is generally benign and parathyroidectomy may not normalize calcium. [9]
- Multiglandular or recurrent disease should trigger hereditary-risk assessment even without a documented family history. [20]

*When inherited disease changes surgical planning or surveillance. [9][14][20][21]*

| Clinical pattern | Most relevant concern | Action |
| --- | --- | --- |
| Hypercalcemia, nonsuppressed PTH, urine calcium <100 mg/24 hours | FHH can mimic PHPT. [21] | Calculate calcium-creatinine clearance ratio before surgery. [9][21] |
| Calcium-creatinine clearance ratio <0.02 | FHH is favored. [9] | Reconsider operative indication and evaluate for inherited calcium-sensing receptor disease as clinically appropriate. [9] |
| PHPT age ≤40 years, multiglandular disease, recurrent disease, or family history | Heritable PHPT is more likely and may signal syndromic disease. [20] | Offer germline testing and direct syndrome-specific surveillance if a pathogenic variant is identified. [20] |
| Parathyroid carcinoma, cystic adenoma, jaw-tumor phenotype, or MEN phenotype | CDC73- or MEN-associated disease is a concern. [14] | Use a germline panel including MEN1, RET, CDKN1B, and CDC73. [14] |

## Who should be referred for parathyroidectomy?

Surgery is curative and should be discussed early, including in many patients without classic symptoms.

Refer patients with symptomatic PHPT for parathyroidectomy. The American Association of Endocrine Surgeons recommends surgery for all symptomatic patients; parathyroidectomy is the only definitive treatment and should be considered for most patients labeled asymptomatic. Early referral to an experienced endocrine surgeon is appropriate after biochemical diagnosis. [4][6][24]

For apparently asymptomatic PHPT, identify renal, skeletal, biochemical, and age-related indications using current consensus criteria during the preoperative assessment. In a surgical cohort, the most frequent guideline-based indications were degree of hypercalcemia (51%), osteoporosis (28%), and nephrolithiasis (27%); patients younger than 50 years remain an established guideline-defined group for operative consideration. [18]

Do not use absence of a classic indication as an automatic reason to withhold referral. Neurocognitive symptoms and osteopenia were common even among patients who did not meet established criteria, and the decision should incorporate disease manifestations, operative fitness, and informed patient preferences. [18][21]

Discuss the expected long-term tradeoff rather than framing surgery only as biochemical correction. In a national cohort, 10-year major osteoporotic fracture incidence was 5.20% after parathyroidectomy versus 7.91% without surgery; 10-year chronic kidney disease incidence was 21.2% versus 33.6%, respectively. Observational associations should inform shared decision-making rather than substitute for individualized assessment. [17]
- Symptomatic disease: refer for parathyroidectomy. [4][6]
- Asymptomatic disease: actively evaluate hypercalcemia severity, osteoporosis, nephrolithiasis, and age younger than 50 years rather than defaulting to observation. [18]
- Patients with neurocognitive complaints or osteopenia warrant individualized surgical discussion even when formal criteria are not met. [18][21]

### Preoperative localization and intraoperative strategy

After the decision for surgery, obtain localization imaging to support focused or bilateral exploration planning. Imaging is used to localize adenomas, while biochemical testing establishes the diagnosis; negative or discordant studies do not exclude surgery. [2][23]

Intraoperative rapid PTH monitoring may support assessment of operative biochemical response, but published work notes that there is no universal consensus on the best operative approach or quick-PTH implementation. Selection of focused versus broader exploration should therefore be integrated with localization results, hereditary-risk features, and surgeon expertise. [3]
- Negative localization should not be interpreted as negative PHPT. [2][23]
- Multiglandular or hereditary-risk disease should influence operative planning beyond a single localized lesion. [14][20]

*Operative decision framework for biochemically confirmed PHPT. [4][6][17][18][21][23]*

| Decision point | Finding | Action |
| --- | --- | --- |
| Symptoms | Symptomatic PHPT | Refer for parathyroidectomy; surgery is definitive therapy. [4][6] |
| Asymptomatic target-organ assessment | Hypercalcemia severity, osteoporosis, nephrolithiasis, or age <50 years | Refer for surgical evaluation using consensus criteria and patient-specific operative risk. [18] |
| Localization | Biochemical diagnosis established and surgery planned | Use imaging for lesion localization and operative planning. [23] |
| Localization discordance | Negative or discordant studies | Do not exclude parathyroidectomy solely on imaging grounds. [2] |
| Long-term outcomes discussion | Patient weighing surgery versus nonsurgical management | Discuss observational 10-year fracture and CKD outcome differences alongside individual comorbidity and preferences. [17] |

## Manage patients who defer or cannot undergo surgery

Medical therapy controls selected biochemical consequences but does not replace curative parathyroidectomy.

Use nonsurgical management when the patient cannot undergo or declines parathyroidectomy, or while definitive treatment is being arranged. Observation without intervention is an alternative in asymptomatic patients without organ manifestations and with only mild hypercalcemia, whereas parathyroidectomy remains the only curative intervention. [12][24]

Do not restrict calcium intake solely because PHPT is present. For patients managed without surgery, calcium intake should follow standard population guidance. Measure 25-hydroxyvitamin D and replete a low value to at least 50 nmol/L (20 ng/mL); a target of at least 75 nmol/L (30 ng/mL) is also recommended as a reasonable goal. [24]

Consider cinacalcet when reduction or normalization of serum calcium is the treatment objective and surgery is not feasible, is declined, or PHPT persists after parathyroidectomy. Available evidence indicates that cinacalcet can normalize calcium and lower PTH, including in persistent postoperative disease, but it has not shown a significant improvement in areal bone mineral density during long-term treatment. [13]

Reassess surveillance suitability when calcium rises, renal stones develop, skeletal disease emerges, or patient preferences change. Real-world adherence to monitoring recommendations is variable, and an initially nonsurgical plan should not become indefinite without periodic reconsideration of surgery. [7][12]
- Maintain usual recommended calcium intake; do not prescribe calcium restriction as PHPT treatment. [24]
- Correct low 25-hydroxyvitamin D to at least 20 ng/mL; 30 ng/mL is a reasonable target. [24]
- Use cinacalcet for calcium control when surgery is unavailable, declined, or unsuccessful; do not expect it to improve bone density. [13]
- Reopen surgical referral when renal, skeletal, or biochemical progression occurs. [12]

### Postoperative calcium risk

Assess and correct vitamin D insufficiency before parathyroidectomy when possible. A meta-analysis of 4,120 patients found that preoperative 25-hydroxyvitamin D at or above 75 nmol/L was associated with a 44% lower incidence of postoperative hypocalcemia compared with concentrations below that threshold; concentrations of 50 to 75 nmol/L did not show significant protection. [11]
- A preoperative 25-hydroxyvitamin D target of at least 75 nmol/L may reduce postoperative hypocalcemia risk. [11]
- Patients with lower preoperative vitamin D require attention to postoperative hypocalcemia and hungry-bone physiology. [11]

*Nonsurgical and perioperative management choices. [11][13][24]*

| Clinical objective | Intervention | Expected effect or limitation |
| --- | --- | --- |
| Avoid nutritional worsening during observation | Maintain calcium intake according to standard recommendations; do not restrict calcium. [24] | Calcium restriction is not recommended for PHPT managed without surgery. [24] |
| Correct vitamin D deficiency | Replete low 25-hydroxyvitamin D to ≥50 nmol/L (20 ng/mL); ≥75 nmol/L (30 ng/mL) is a reasonable goal. [24] | Preoperative concentrations ≥75 nmol/L were associated with 44% lower postoperative hypocalcemia incidence. [11] |
| Lower serum calcium when surgery is not pursued | Consider cinacalcet. [13] | Can normalize calcium and lower PTH but has no significant areal BMD effect in long-term data. [13] |
| Persistent PHPT after surgery | Consider cinacalcet when repeat curative surgery is not undertaken. [13] | Can normalize calcium and lower PTH in persistent postoperative PHPT. [13] |

## Use surveillance to detect a new surgical indication

Observation requires active reassessment for renal, skeletal, and biochemical progression.

For patients initially observed, monitor for changes that alter the surgical decision: worsening hypercalcemia, nephrolithiasis, osteoporosis, and renal decline are clinically meaningful PHPT outcomes. PHPT is associated with fractures, kidney stones, and chronic kidney disease, and a large cohort found lower 10-year incidence of major osteoporotic fracture and CKD among surgically treated patients. [17][20]

At each follow-up, revisit whether the patient still prefers observation and whether new end-organ disease has emerged. This is particularly important in older adults, in whom many patients have guideline-based indications driven by hypercalcemia, osteoporosis, or nephrolithiasis despite being labeled asymptomatic. [18]

Escalate to endocrine surgery rather than repeating localization studies indefinitely when biochemical PHPT is established and operative indications or clinically important manifestations are present. Less than half of patients fulfilling surgical criteria receive parathyroidectomy, despite guideline-based support for surgery. [1]
- Treat nephrolithiasis, osteoporosis, worsening calcium burden, and renal deterioration as triggers to reassess operative management. [17][18][20]
- Do not let an asymptomatic label override newly recognized target-organ involvement. [18]
- When surgery is indicated, referral should not be delayed by inadequate or nonlocalizing imaging. [1][2][23]

*Events during observation that should prompt renewed surgical review. [17][18][20]*

| New finding | Why it matters | Next step |
| --- | --- | --- |
| Nephrolithiasis | Renal stones are a common guideline-based surgical indication and PHPT morbidity. [18][20] | Refer or re-refer for parathyroidectomy assessment. [4][6] |
| Osteoporosis or major osteoporotic fracture | Skeletal disease is a common operative indication; fracture risk is a recognized PHPT morbidity. [18][20] | Reassess candidacy for definitive surgery. [4][6] |
| Progressive renal dysfunction | CKD is a clinically important PHPT-associated outcome. [17][20] | Reevaluate surgery versus continued medical management. [17] |
| Increasing biochemical burden | Extent of hypercalcemia was the most common guideline-based surgical indication in one operative cohort. [18] | Review operative indication and patient preference. [18][21] |

## References
1. Quality Indicators for the Diagnosis and Management of Primary Hyperparathyroidism — jamanetwork.com — https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2787786
2. Intraoperative Parathyroid Hormone Monitoring Criteria in Primary ... — jamanetwork.com — https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2827787
3. Pitfalls of Intraoperative Quick Parathyroid Hormone Monitoring and ... — jamanetwork.com — https://jamanetwork.com/journals/jamasurgery/fullarticle/212549
4. AAES Guidelines for Primary Hyperparathyroidism Management — jamanetwork.com — https://jamanetwork.com/journals/jamasurgery/fullarticle/2542667
5. A 10-Year Prospective Study of Primary Hyperparathyroidism with or ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM199910213411701
6. Primary Hyperparathyroidism: Diagnosis, Indications for Surgery, and Perioperative Management - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1555415519305926
7. Clinical Management of Primary Hyperparathyroidism and Thresholds for Surgical Referral: A National Study Examining Concordance Between Practice Patterns and Consensus Panel Recommendations - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1530891X20403052
8. Management of Hyperparathyroidism in Kidney Transplantation Candidates: A Need for Consensus - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1530891X20350576
9. Abstract #1408170: Familial Hypocalciuric Hypercalcemia, Primary Hyperparathyroidism, or Both? - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1530891X23001970
10. Primary hyperparathyroidism - Current Opinion in Oncology — journals.lww.com — https://journals.lww.com/co-oncology/fulltext/2008/01000/primary_hyperparathyroidism.8.aspx
11. Preoperative 25(OH)D≥75 nmol/L is associated with... : International Journal of Surgery — journals.lww.com — https://journals.lww.com/international-journal-of-surgery/_layouts/15/oaks.journals/downloadpdf.aspx?an=01279778-202603000-00201
12. Individualized management of primary... : Journal of Internal Medicine — journals.lww.com — https://journals.lww.com/00004777-202606000-00002
13. Cinacalcet Treatment of Primary Hyperparathyroidism - Rothe - 2011 - International Journal of Endocrinology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2011/415719
14. Indian Journal of Endocrinology and Metabolism — journals.lww.com — https://journals.lww.com/indjem/fulltext/2025/11000/targeted_next_generation_sequencing_of_men_1,_ret,.12.aspx
15. Primary Hyperparathyroidism in Adults: Recent Developments in ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.5694/mja2.70194
16. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/27613721
17. Patient Characteristics, Management, and Outcomes in a Novel Cohort of Primary Hyperparathyroidism | Endocrine Society — www.endocrine.org — https://www.endocrine.org/journals/journal-of-the-endocrine-society/a-novel-cohort-of-primary-hyperparathyroidism
18. Older Patients With Asymptomatic PHPT | Endocrine Society — www.endocrine.org — https://www.endocrine.org/journals/journal-of-the-endocrine-society/older-patients-with-asymptomatic-phpt
19. Serum Phosphate in Primary Hyperparathyroidism | Endocrine Society — www.endocrine.org — https://www.endocrine.org/journals/jcem/serum-phosphate-in-primary-hyperparathyroidism
20. Molecular and Clinical Spectrum of Primary Hyperparathyroidism | Endocrine Society — www.endocrine.org — https://www.endocrine.org/journals/endocrine-reviews/molecular-and-clinical-spectrum-of-primary-hyperparathyroidism
21. Should I refer my patient for a parathyroidectomy? | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/content/91/5/279
22. Enterovirus Infections - AAP Publications — publications.aap.org — https://publications.aap.org/pediatricsinreview/issue-pdf/824673
23. Contemporary Multimodality Imaging of Primary Hyperparathyroidism — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/rg.210170
24. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/25162668

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.